A Pilot Study on the Effect of Vitamin D Treatment in Patients With Statin-Associated Myalgia

Avera McKennan Hospital & University Health Center

Status and phase: Withdrawn; Phase 1

Conditions: Hyperlipidemia

Treatments: Dietary Supplement: Vitamin D3; Other: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT01274104

ARI-1350-Myalgia

Details and patient eligibility

About

The purpose of this study is to measure the effect vitamin D has in alleviating muscle pain or aches that may be caused by taking certain medications for treating high cholesterol.

Full description

Participation in this study will consist of at least two study visits, expected to occur over a period of up to four weeks. Study-related medication will be provided at no cost to participants. Participants will receive either Vitamin D or placebo (sugar pill).

Sex: All

Ages: 18 to 88 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men and women who are between the ages of 18 and 88 years old
• A muscle symptom defined as any of the following: Myalgia (muscle aches with normal CK); Myopathy (muscle aches with increased CK up to 5 times above the upper limit of normal); or Myopathy for the purpose of further evaluation (muscle aches with increased CK up to 5 times the upper limit of normal)

Exclusion criteria

• Women who are pregnant, breastfeeding or planning to become pregnant
• Morbidly obese with a BMI >40 kg/m2
• Travel to southern states, areas near the Equator, etc., or use of artificial tanning beds, such that study participants have increased sunlight/UV rays exposure in the past 30 days or at any point during the trial
• Currently (within the last 2 weeks) using any of the following supplements: Vitamin D-3 (Cholecalciferol) of more than 400 IU orally daily, which would not exclude typical multi-vitamin use; Vitamin D-2 (Ergocalciferol); Calcitriol; or Coenzyme Q10
• Documented to be hyperglycemic or laboratory results show hyperglycemia prior to randomization
• Renal dysfunction defined as glomerular filtration rate less than 60 mL/min.
• Documented to have parathyroid abnormalities or parathyroid hormone laboratory results show the study participant is outside of the normal limits

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

0 participants in 2 patient groups, including a placebo group

Vitamin D

Active Comparator group

Description:

Subjects will take 5,000 IU-capsules of vitamin D3 three times a day (for a total of 15,000 IU) for 14 days

Treatment:

Dietary Supplement: Vitamin D3

Control

Placebo Comparator group

Description:

Subjects will take 3 capsules of placebo every day for 14 days

Treatment:

Other: Placebo